1. Home
  2. WINT vs GNLN Comparison

WINT vs GNLN Comparison

Compare WINT & GNLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WINT
  • GNLN
  • Stock Information
  • Founded
  • WINT 1992
  • GNLN 2005
  • Country
  • WINT United States
  • GNLN United States
  • Employees
  • WINT N/A
  • GNLN N/A
  • Industry
  • WINT Biotechnology: Biological Products (No Diagnostic Substances)
  • GNLN Durable Goods
  • Sector
  • WINT Health Care
  • GNLN Consumer Discretionary
  • Exchange
  • WINT Nasdaq
  • GNLN Nasdaq
  • Market Cap
  • WINT 1.5M
  • GNLN 1.6M
  • IPO Year
  • WINT 1995
  • GNLN 2019
  • Fundamental
  • Price
  • WINT $1.20
  • GNLN $0.27
  • Analyst Decision
  • WINT Hold
  • GNLN
  • Analyst Count
  • WINT 1
  • GNLN 0
  • Target Price
  • WINT $350.00
  • GNLN N/A
  • AVG Volume (30 Days)
  • WINT 7.7M
  • GNLN 385.8K
  • Earning Date
  • WINT 04-15-2025
  • GNLN 03-21-2025
  • Dividend Yield
  • WINT N/A
  • GNLN N/A
  • EPS Growth
  • WINT N/A
  • GNLN N/A
  • EPS
  • WINT N/A
  • GNLN N/A
  • Revenue
  • WINT N/A
  • GNLN $13,275,000.00
  • Revenue This Year
  • WINT N/A
  • GNLN $1,541.21
  • Revenue Next Year
  • WINT N/A
  • GNLN N/A
  • P/E Ratio
  • WINT N/A
  • GNLN N/A
  • Revenue Growth
  • WINT N/A
  • GNLN N/A
  • 52 Week Low
  • WINT $1.10
  • GNLN $0.26
  • 52 Week High
  • WINT $737.50
  • GNLN $21.80
  • Technical
  • Relative Strength Index (RSI)
  • WINT 27.23
  • GNLN 17.91
  • Support Level
  • WINT $1.22
  • GNLN $0.26
  • Resistance Level
  • WINT $2.17
  • GNLN $0.37
  • Average True Range (ATR)
  • WINT 0.32
  • GNLN 0.05
  • MACD
  • WINT 0.20
  • GNLN 0.01
  • Stochastic Oscillator
  • WINT 3.54
  • GNLN 0.76

About WINT Windtree Therapeutics Inc.

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

About GNLN Greenlane Holdings Inc.

Greenlane Holdings Inc is a distributor of vaporization products and consumption accessories in the United States. It offers a selection of stock-keeping units including vaporizers and parts, cleaning products, grinders and storage containers, pipes, rolling papers and customized lines of premium specialty packaging. The company markets and sells its products in both the business to business and business to consumer sectors of the marketplace. Its geographical segment includes the United States; Canada and Europe. It derives a majority of revenue from the United States.

Share on Social Networks: